growth hormone mechanism: Frequently asked questions

You're observing tachyphylaxis—short-interval repeated stimulation reduces receptor responsiveness temporarily. Space doses at least 6 hours apart to allow GH levels and receptor sensitivity to return to baseline between administrations. Most protocols structure this as pre-bed and morning dosing (roughly 8–10 hours apart) to align with circadian GH rhythms. If research design requires more frequent dosing, rotating between Ipamorelin and a GHRH analog like Sermorelin can maintain pulsatility without receptor fatigue—each compound acts on different receptors, so they don't compete for the same binding sites.

Verify peptide storage integrity, confirm injection timing consistency, and assess dietary adherence. Plateaus often reflect protocol drift, not pharmacological tolerance. Tesamorelin's mechanism does not produce tachyphylaxis, but real-world adherence does decline over extended protocols. If storage and dosing are confirmed optimal, the plateau likely represents the biological limit of VAT reduction for that individual's receptor density and adipocyte responsiveness. Not all subjects achieve 15% VAT reduction. Trial data showed a range of 8–22%, with baseline VAT volume inversely predicting percentage reduction. Subjects with lower baseline VAT (under 120 cm² cross-sectional area) showed smaller absolute reductions. At that point, continued tesamorelin maintains the achieved reduction but does not drive further loss. Discontinuation results in VAT reaccumulation within 26 weeks, so the choice is maintenance dosing or acceptance of regain.

Use Ipamorelin as your primary secretagogue—it's the only ghrelin receptor agonist with published evidence of negligible ACTH and cortisol stimulation even at suprapharmacological doses. GHRP-2, GHRP-6, and Hexarelin all produce measurable cortisol increases due to non-selective receptor activation. This selectivity is why Ipamorelin remains the preferred compound in metabolic research where cortisol would confound insulin sensitivity measurements, and in stress-response studies where isolating GH effects from glucocorticoid effects is essential. If you need even greater GH amplitude without sacrificing selectivity, stack Ipamorelin with CJC-1295—the GHRH analog adds no cortisol response but amplifies the GH pulse significantly.

Refrigerate it immediately and do not use it for research applications requiring precise dosing. Peptide bonds in reconstituted Ipamorelin begin denaturing at temperatures above 8°C, and while six hours at 20–22°C may not destroy 100% of the peptide, you have no way to measure remaining potency. Degraded Ipamorelin doesn't visually change—it remains clear and colorless even when partially denatured. Research protocols depend on dose consistency; using a vial of unknown concentration introduces uncontrolled variables that compromise data integrity. The financial cost of discarding one vial is negligible compared to the research cost of unreliable results across an entire study.

Verify three things before concluding non-responsiveness: peptide storage integrity, reconstitution technique, and baseline pituitary reserve. If Ipamorelin was stored correctly (lyophilized powder at −20°C, reconstituted solution at 2–8°C) and reconstituted with bacteriostatic water using proper aseptic technique, the issue may be endogenous. GH secretagogue responsiveness declines with age as somatotroph density in the anterior pituitary decreases—a 60-year-old research model may produce 40–60% less GH response to the same Ipamorelin dose compared to a 25-year-old model. In such cases, combining Ipamorelin with a GHRH analog like CJC-1295 often restores responsiveness by priming the remaining somatotrophs before triggering secretion.

Refrigerate it immediately and continue the protocol. Short-term temperature excursions under 25°C for fewer than 12 hours typically do not destroy activity, though potency may decline 5–10%. Peptide aggregation and denaturation accelerate exponentially above 8°C, but the process is time-dependent. A vial left on a counter for 6 hours is compromised but not necessarily inert. The conservative approach: discard and reconstitute a fresh vial. The pragmatic approach: continue use and monitor for diminished effect (reduced injection site reaction intensity, absence of transient joint stiffness in weeks 2–4). If clinical endpoints like VAT imaging show expected reduction trajectories, the peptide retained sufficient activity. One temperature excursion does not mandate protocol termination, but repeated excursions accumulate damage.

Pause tesamorelin and consult with a medical advisor before resuming. While transient glucose elevation is common during the acute lipolytic phase, sustained hyperglycemia (>126 mg/dL on two separate fasting measurements) indicates impaired glucose homeostasis that may not resolve spontaneously. The free fatty acids mobilized from visceral adipocytes compete with glucose for oxidation in muscle and liver, a phenomenon called the Randle cycle, which can worsen pre-existing insulin resistance. Clinical trial protocols mandated discontinuation if HbA1c increased by ≥0.5% or fasting glucose exceeded 140 mg/dL. Resuming at a lower dose (1mg daily) after glucose normalizes may allow adaptation with reduced metabolic stress.

Discard the vial and reconstitute a fresh dose. Peptide bonds in tesamorelin begin denaturing at temperatures above 8°C, with degradation accelerating exponentially beyond 15°C. A six-hour room temperature exposure can reduce potency by 40–60%, meaning the nominal 2mg dose delivers only 0.8–1.2mg of active peptide. There is no visual indicator of degradation. The solution remains clear. So temperature discipline is the only safeguard. For multi-day travel, use an insulin cooler with ice packs rated to maintain 2–8°C for 48 hours.

Reduce the dose to 1mg daily for 4 weeks, then re-escalate to 2mg if symptoms resolve. Persistent arthralgia beyond 12 weeks suggests the subject is a high responder with exaggerated GH or IGF-1 elevation. Joint pain from GH is caused by periarticular fluid retention and soft tissue swelling, not cartilage damage. It resolves when GH levels stabilize, which typically occurs by week 12 as compensatory mechanisms (increased natriuresis, receptor downregulation in non-target tissues) adapt. If pain persists beyond that window, the subject's GH response curve is likely on the high end of normal distribution. Dose reduction to 1mg daily lowers peak GH but still stimulates pituitary release. Trials showed 1mg produced approximately half the VAT reduction of 2mg but with significantly lower arthralgia incidence (6% vs 13%). After 4 weeks at 1mg, if symptoms resolve, attempt re-escalation to 1.5mg or alternate-day 2mg dosing. Some subjects tolerate pulsed dosing better than daily dosing due to differences in GH clearance kinetics.

Switch to a different reconstitution technique or evaluate benzyl alcohol sensitivity. Persistent erythema, induration, or pruritus beyond the initial adaptation period suggests either mechanical trauma (injecting too quickly, using a dull needle, or failing to rotate sites) or a hypersensitivity reaction to the preservative in bacteriostatic water. Try injecting over 10 seconds instead of 5, and ensure you're rotating sites by at least 2 inches each day. If reactions continue, consider reconstituting with sterile water for injection instead of bacteriostatic water. This eliminates benzyl alcohol exposure but requires using the entire vial within 24 hours due to lack of bacteriostatic preservation.

Maintain the current dose rather than increasing. Tesamorelin's effect ceiling is reached at 2mg daily. The Phase III trials showed maximal VAT reduction occurred between weeks 20–26, with diminishing returns beyond that point. Plateaus typically reflect the biological limit of receptor-mediated lipolysis at that dose, not treatment failure. Increasing to 3mg or 4mg does not produce proportional additional fat loss but does increase adverse event risk, particularly joint pain and glucose elevation. If further body composition improvement is needed, the addition of a complementary pathway modulator like Ipamorelin. Which stimulates GH via the ghrelin receptor rather than GHRH. Can provide synergistic effect without exceeding single-pathway receptor saturation.

Consider a pulsatile secretagogue protocol with glycemic monitoring, or abandon pharmacological GH elevation entirely in favor of interventions that improve insulin sensitivity first. Resistance training, caloric periodization, or GLP-1 receptor agonists like semaglutide. Growth hormone and insulin are metabolic antagonists. Elevating GH in the presence of baseline insulin resistance accelerates beta-cell exhaustion and progression to type 2 diabetes. The trials excluded subjects with HbA1c above 6.5% for this reason. If your population includes metabolic syndrome, prediabetes, or overt diabetes, tesamorelin is not the appropriate intervention. Address insulin resistance first; GH modulation second. Attempting both simultaneously places subjects at unacceptable hyperglycemia risk and confounds attribution of metabolic outcomes.